Track Amphastar Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Amphastar Pharmaceuticals, Inc. AMPH · Stock Open Amphastar Pharmaceuticals, Inc. in new tab

29.37 USD
P/E
13.47
EPS
2.18
P/B
1.54
ROE
12.44
Beta
0.94
Target Price
24.50 USD
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc.

🧾 Earnings Recap – Q1 2026

Amphastar’s stock dropped sharply by 23.2% after earnings, reflecting investor disappointment over ongoing pricing pressure, rebate-related revenue headwinds, and mixed segment performance despite stable baseline business and pipeline progress.

  • Net revenues reached approximately $171.2 million, driven primarily by recent product launches but offset by pricing pressure and product mix shifts in legacy products.
  • BAQSIMI revenue was about $32 million but impacted by higher rebates, channel mix, and greater government program utilization, masking an underlying 8% volume growth.
  • Primatene MIST generated roughly $30 million, with store-level sales up 6.5% year-over-year, supported by marketing efforts.
  • Pricing and competitive intensity remain variable and continue to pressure margins and top-line stability in legacy products.
  • The company’s pipeline shows progress with expected biosimilar and proprietary launches in 2027, though these have yet to meaningfully impact current financials.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E13.47
EPS2.18
Book Value19.10
Price to Book1.54
Debt/Equity84.92
% Insiders31.012%
Growth
Revenue Growth0.08%
Earnings Growth1.35%
Estimates
Forward P/E8.83
Forward EPS3.33
Target Mean Price24.50

DCF valuation

Model fair value for Amphastar Pharmaceuticals, Inc. (AMPH)
Result
Sign in to run the valuation for AMPH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Hold · mean target 24.50 USD (low 20.00, high 30.00) · as of 14 Nov 2026
Low 20.00
Mean 24.50
High 30.00
Price 29.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Amphastar Pharmaceuticals, Inc. Logo Amphastar Pharmaceuticals, Inc. Analysis (AMPH)

United States Health Care Official Website Stock

Is Amphastar Pharmaceuticals, Inc. a good investment? Amphastar Pharmaceuticals, Inc. (AMPH) is currently trading at 29.37 USD. Market analysts have a consensus price target of 24.50 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 13.47. This relatively low multiple may signal that Amphastar Pharmaceuticals, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Amphastar Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 3.33.

Investor FAQ

Does Amphastar Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Amphastar Pharmaceuticals, Inc.?

Amphastar Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 2.18.

Company Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Exchange Ticker
FRA (Germany) 29A.F
NMS (United States) AMPH
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2010
0.30 USD
June 30, 2010 0.3000
▸2009
0.30 USD
June 30, 2009 0.3000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion